Please use this identifier to cite or link to this item:
|Title:||Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge|
|Authors:||de Camargo, Tarsila Mendes|
de Freitas, Elisangela Oliveira
Gimenez, Alba Marina [UNIFESP]
Lima, Luciana Chagas
Caramico, Karina de Almeida
Francoso, Katia Sanches
Ertl, Hildegund C. J.
Nussenzweig, Ruth S.
Rodrigues, Mauricio M. [UNIFESP]
Soares, Irene S.
|Publisher:||Nature Publishing Group|
|Citation:||Scientific Reports. London, v. 8, p. -, 2018.|
|Abstract:||Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-All(FL)) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-All(CT)) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against P. vivax malaria.|
|Appears in Collections:||Artigo|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.